GERMAN HODGKIN STUDY GROUP PHASE I TRIAL OF DOXORUBICIN, VINBLASTINE, DACARBAZINE, AND LENALIDOMIDE (AVD-REV) FOR ELDERLY HODGKIN LYMPHOMA PATIENTS ? FINAL ANALYSIS
Author(s): ,
Boris Boell
Affiliations:
Hematology,GHSG, University Hospital,Cologne,Germany
,
Annette Pluetschow
Affiliations:
Hematology,GHSG,Cologne,Germany
,
Dennis Eichenauer
Affiliations:
Hematology,GHSG,Cologne,Germany
,
Bastian von Tresckow
Affiliations:
Hematology,GHSG,Cologne,Germany
,
Johannes Atta
Affiliations:
hematology,University Hospital,frankfurt,Germany
,
Michael Pfreundschuh
Affiliations:
Hematology,University Hospital,Homburg,Germany
,
Feuring-Buske Michaela
Affiliations:
Hematology,University Hospital,Ulm,Germany
,
Martin Vogelhuber
Affiliations:
Hematology,University Hospital,Regensburg,Germany
,
Martin Sökler
Affiliations:
hematology,University Hospital,Tuebingen,Germany
,
Michael Fuchs
Affiliations:
Hematology,GHSG,Cologne,Germany
,
Andreas Engert
Affiliations:
Hematology,GHSG,Cologne,Germany
Peter Borchmann
Affiliations:
Hematology,GHSG,Cologne,Germany
EHA Learning Center. Boell B. Jun 14, 2015; 103189
Disclosure(s): German Hodgkin Study Group
Hematology
Boris Boell
Boris Boell

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: S805

Type: Oral Presentation

Presentation during EHA20: From 14.06.2015 08:00 to 14.06.2015 08:15

Location: Room Lehar 3 + 4

Background
About 30% of all Hodgkin Lymphoma (HL) patients are ≥60 years old. ABVD is standard of care for these patients, although outcome and feasibility are poor, one limitation being bleomycin-induced pulmonary toxicity. 

Aims
We thus replaced bleomycin with lenalidomide (Revlimid®), and initiated the AVD-Rev phase-I trial (NCT01569204) for 60-75 year-old patients with 1st diagnosis of early unfavorable- or advanced-stage HL, good performance status (ECOG/WHO ≤2), and no severe organ dysfunction.

Methods
Depending on stage and response at interim staging, patients received 4-8 cycles of AVD-Rev followed by radiotherapy with prophylactic anticoagulation (ASA or heparin). The daily lenalidomide dose for the first patient was 5mg; possible dose levels ranged from 5 to 40mg. Thromboembolism ≥CTC II°, hematological toxicity as severe cytopenia (ANC< 500/μl >7days with G-CSF and thrombocytopenia < 25.000/μl), and complications as neutropenic fever and prolonged therapy delay were considered as dose limiting toxicities (DLT) if they occurred during the first 4 cycles.

Results
 25 patients (median age: 67, range 61-76) and a CIRS-G comorbidity score of up to 7 points (range 0-7) were assigned to dose levels 5mg (n=1), 10mg (n=1), 15mg (n=1), 20mg (n=6), and 25mg (n=16). 15 patients were male, 68% had advanced stage-HL, and 80% had B-symptoms.?After DLT evaluation of 20 patients, a pre-specified stopping criterion was reached with a recommended dose for a phase II trial of 25mg.?Dose delivery was high with a median relative dose intensity of 97% (range 49%>104%; mean 91%). However, CTC III°-IV° toxicities occurred in all 22 patients treated at the 20mg and 25mg dose levels. DLTs were observed in 1 of 6 and 5 of 16 patients at 20mg and 25mg, respectively, and were mainly hematologic but included 3 thromboembolic events despite ASA prophylaxis. No DLT occurred in patients receiving < 20mg lenalidomide. Of note in these vulnerable patients, no treatment related deaths occurred.?Overall response rates were 80% for all patients (20/25) and 86% (19/22) for patients receiving ≥20mg lenalidomide. At 19 months median observation time, 5 patients had disease progression and 4 patients died. The one-year estimates for progression-free (PFS) and overall survival (OS) are 75% [95%> CI: 53-88%] and 92% [95%>CI: 71-98%], respectively. Final results on PFS and OS with two years follow-up will be presented at the EHA congress 2015.

Summary
AVD-Rev is toxic but feasible and highly effective in this vulnerable population of elderly HL patients. 

Keyword(s): Chemotherapy, Elderly, Imids, Immunotherapy

Session topic: Progess in Hodgkin lymphoma therapy: Incorporation of novel agents and reduction of side effects
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings